Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;41(2):247-252.
doi: 10.1002/clc.22891. Epub 2018 Mar 1.

What the Women's Health Initiative has taught us about menopausal hormone therapy

Rebecca C Chester  1 , Juliana M Kling  2 , JoAnn E Manson  3
Affiliations
Review

What the Women's Health Initiative has taught us about menopausal hormone therapy

Rebecca C Chester et al. Clin Cardiol. 2018 Feb.

Abstract

Our understanding of the complex relationship between menopausal hormone therapy (MHT) and cardiovascular disease (CVD) risk has been informed by detailed analyses in the Women's Health Initiative (WHI), the largest randomized, placebo-controlled trial evaluating MHT in postmenopausal women. Although the WHI demonstrated increased risk of CVD events with MHT in the overall cohort, subsequent secondary analyses demonstrated that these risks were influenced by the woman's age and time since menopause, with lower absolute risks and hazard ratios for younger than older women. As MHT is the most effective treatment for the vasomotor symptoms of menopause, it is important to understand its risks and how to conduct risk stratification for symptomatic women. In addition to reviewing the WHI findings, studies pre- and post-WHI are reviewed to describe the relationship between MHT and CVD risk in menopausal women. The absolute risks of adverse cardiovascular events for MHT initiated in women close to menopause are low, and all-cause mortality effects are neutral or even favorable for younger menopausal women. The WHI has advanced and refined our understanding of the relationship between MHT and CVD risk. Although MHT should not be used for CVD prevention, absolute risks of CVD are low when MHT is started close to menopause in healthy women and hazard ratios tend to be lower for younger than older women. For women in early menopause and without contraindications to treatment, the benefits of MHT are likely to outweigh the risks when used for menopausal symptom management.

Keywords: Acute Coronary Care; Cardiovascular Risk; Menopausal Hormone Therapy; Women's Heart Disease; timing hypothesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Design of the Women's Health Initiative clinical trial and observational study . The Women's Health Initiative Study Group. Control Clin Trials. 1998;19:61–109. - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed
    1. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712. - PubMed
    1. Barrett‐Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861–1867. - PubMed
    1. Bush TL, Barrett‐Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev. 1985;7:89–104. - PubMed